Neoplastic disease after liver transplantation: Focus on de novo neoplasms.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4528018)

Published in World J Gastroenterol on August 07, 2015

Authors

Patrizia Burra1, Kryssia I Rodriguez-Castro1

Author Affiliations

1: Patrizia Burra, Kryssia I Rodriguez-Castro, Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, 35128 Padua, PD, Italy.

Articles cited by this

(truncated to the top 100)

Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46

Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06

Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06

Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17

Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54

Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol (2002) 3.20

Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64

Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res (1990) 2.49

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int (2014) 2.26

Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25

Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15

Preventable exposures associated with human cancers. J Natl Cancer Inst (2011) 2.14

Donors with central nervous system malignancies: are they truly safe? Transplantation (2003) 2.12

Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl (2002) 2.00

Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl (2008) 1.97

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94

Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant (2010) 1.93

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93

The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol (2004) 1.92

Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol (2000) 1.90

The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88

Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol (2005) 1.86

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76

Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66

Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 1.66

Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59

Cancers complicating organ transplantation. N Engl J Med (1990) 1.57

Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med (2005) 1.55

Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54

Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52

"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52

Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation (2004) 1.51

Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation (2007) 1.51

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant (2004) 1.50

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (2009) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44

The changing pattern of posttransplant malignancies. Transplant Proc (1991) 1.42

Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol (2012) 1.41

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40

Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation (2002) 1.33

mTOR inhibitors: an overview. Liver Transpl (2001) 1.32

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28

mTOR, cancer and transplantation. Am J Transplant (2008) 1.24

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg (2008) 1.22

Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant (2009) 1.20

Rapamycin: clinical results and future opportunities. Transplantation (2001) 1.20

Transplant tumor registry: donor related malignancies. Transplantation (2002) 1.19

Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18

Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology (2009) 1.18

Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.17

Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation (2003) 1.16

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16

Transmission of donor melanoma by organ transplantation. Lancet Oncol (2010) 1.15

An update on donor-derived disease transmission in organ transplantation. Am J Transplant (2011) 1.15

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14

Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation (2003) 1.14

Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int (2010) 1.14

An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation (1995) 1.13

Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res (2007) 1.13

Donor transmitted malignancies. Ann Transplant (2004) 1.13

A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg (2007) 1.12

Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol (2009) 1.11

Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem (2010) 1.09

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer (2013) 1.09

De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant (2004) 1.09

The effect of immunosuppression on pre-existing cancers. Transplantation (1993) 1.08

Burden of de novo malignancy in the liver transplant recipient. Liver Transpl (2012) 1.07

Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol (1996) 1.07

Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol (2001) 1.07

Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation (2000) 1.06

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer (1997) 1.06

The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis (2001) 1.06

Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis (2003) 1.06

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation (2010) 1.06

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06

Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation (1999) 1.05

European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant (2002) 1.04

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc (2008) 1.03

Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis (2009) 1.01

Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol (2011) 1.01

De novo tumors after liver transplantation: a single-institution experience. Liver Transpl (2002) 1.00

Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol (2013) 1.00